Diagnostic Pathway following Child Vision Screening
Summarises the referral pathway for children who fail vision screening aged 4 to 5 years as part of the childhood vision screening programme.
Our range of high-quality guidance helps to maintain standards in the planning, practice and commissioning of patient care. Our clinical guidelines provide evidence-based recommendations across all aspect of care or of eye conditions; Concise Practice Points make recommendations for less frequent and targeted clinical situations, succinctly describing the scientific and clinical evidence alongside expert input to enhance clinician and patient decision making. Our Commissioning guidance supports eye units to develop services to meet local population needs.
Summarises the referral pathway for children who fail vision screening aged 4 to 5 years as part of the childhood vision screening programme.
A single point of reference for busy clinicians when managing these complex patients from differential diagnosis, through long-term management, to discharge. It also covers provision of support for patients and carers throughout and beyond clinical care pathways.
This document provides advice to clinicains on referring suspected ocular oncology cases to the nationally designated ocular oncology centres.
Recommendations for diagnosis and management
These guidelines cover primary angle-closure only and specifically excludes secondary disease such as that resulting from uveitis or neovascularization. It is primarily for clinicians involved in eye care in the community and in hospital eye services and aims to inform clinicians. 1. What is the accuracy of current diagnostic tests 2. What is the effectiveness of different interventions 3. When to refer to hospital eye services 4. When to discharge to community Executive Summary
Summarises existing guidelines to show how currently available training and qualifications enable Health Care Professionals (HCPs) to deliver care for patients with different categories of GLAUC-STRAT-FAST risk.
This guideline covers the screening and treatment of reinopathy of prematurity. Retinopathy of prematurity (ROP) is a potentially blinding condition affecting low gestation and very low birth weight infants. Worldwide it is a major cause of preventable blindness. Screening for ROP is undertaken to identify ROP that requires treatment. This evidence-based guideline for the treatment of ROP was developed by a guideline development group (GDG) of The Royal College of Ophthalmologists (RCOphth), the UK special interest group of ROP screeners and treaters (ROP-SIG) and the charity Bliss. The guideline was produced according to RCOphth standards for guideline development.
This guideline update includes responses to the consultation in October 2021. It incorporates the impact of new imaging modalities and their findings on the management of retinal vein occlusion. The use of intravitreal agents in the management of retinal vein occlusion has been updated to reflect the increasing body of literature on its use along with the impact this treatment has on the natural history and complications of retinal vein occlusion. Scope: diagnostic tools, management, service set up and delivery of optimal care pathway for patients with RVO.
The aim of this document is to provide advice on the identification and management of an outbreak of post ophthalmic procedure (post-op) endophthalmitis. The guidance will concentrate particularly on cataract surgery, but the principles and much of the detail are applicable to other intraocular procedures including intravitreal injections.